---
title: "CHINARES PHARMA's biopharmaceutical innovation drug \"Puyouke\" has been approved for new indications"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/258985234.md"
description: "China Resources Pharmaceutical's Tian Shi Li Biopharmaceutical Co., Ltd. has been approved by the National Medical Products Administration for the new indication of acute ischemic stroke for the biological innovative drug Puyouke. This drug was originally a Class 1 biological innovative drug for the indication of acute ST-segment elevation myocardial infarction, and this is its second indication approved domestically"
datetime: "2025-09-26T04:14:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258985234.md)
  - [en](https://longbridge.com/en/news/258985234.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258985234.md)
---

# CHINARES PHARMA's biopharmaceutical innovation drug "Puyouke" has been approved for new indications

China Resources Pharmaceutical (03320.HK) announced that its subsidiary Tianjin Tasly Biological Pharmaceutical Co., Ltd. has received the "Drug Registration Certificate" issued by the National Medical Products Administration, approving the additional indication of the self-owned intellectual property biological innovative drug recombinant human urokinase (Pu You Ke) for thrombolytic treatment of acute ischemic stroke.

Pu You Ke is a Class 1 biological innovative drug approved during the "11th Five-Year Plan" period under the national "Major New Drug Creation" science and technology major project, with the indication for acute ST-segment elevation myocardial infarction. This acute ischemic stroke indication is the second indication approved for this drug in China

### Related Stocks

- [03320.HK](https://longbridge.com/en/quote/03320.HK.md)

## Related News & Research

- [Kelun-Biotech Receives Over RMB700 Million from MediLink Settlement](https://longbridge.com/en/news/289527164.md)
- [10:01 ETIn Vitro Toxicology Testing Market worth $20.97 billion by 2031 | MarketsandMarkets™](https://longbridge.com/en/news/289608726.md)
- [LongBio Pharma’s LP-003 Hits Phase III Goals in Seasonal Allergic Rhinitis](https://longbridge.com/en/news/289522734.md)
- [Simcere Pharma Reveals Research Deal With Stanford Medicine To Develop Treatment For IPF](https://longbridge.com/en/news/289571120.md)
- [BeOne Medicines Sets Out Board and Committee Structure to Bolster Governance](https://longbridge.com/en/news/289523795.md)